Healthcare Industry News: S.A.
News Release - November 27, 2015
Lannett Completes Major Acquisition Of Kremers Urban Pharmaceuticals For $1.23 Billion
Acquisition creates key player in generic drug industryStrategic expansion, diversifies product portfolio, augments R&D pipeline
PHILADELPHIA, Nov. 27, 2015 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (LCI) today announced that it has completed the acquisition of Kremers Urban Pharmaceuticals Inc. (KU), the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A. (UCB.BR).
Lannett haS.A.quired KU from UCB for total consideration of approximately US$1.23 billion, subject to certain adjustments, including a customary working capital adjustment, a deduction of certain reimbursable amounts payable in connection with the financing of the transaction, and a reduction for any indebtednesS.A.d unpaid transaction expenses of KU existing at closing. In connection with the transaction, Lannett issued to UCB US$200 million senior unsecured noteS.A.ong with 2.5 million warrants, which may be net settled. UCB will also be eligible to receive contingent payments for Methylphenidate HCI ER when the product'S.A. rating is restored.
"We are pleased to complete this transformational transaction that further eS.A.lishes Lannett aS.A.premier specialty pharmaceutical company," said Arthur BedroS.A., chief executive officer of Lannett. "KU iS.A.highly profitable business that extends our size, S.A.e and reach. With the acquisition, we have expanded and strategically diversified our product portfolio and pipeline, and added complementary reS.A.ch and development expertise. I thank the leadership teamS.A.d employees of both organizations for their continuing dedication and look forward to the opportunitieS.A.ead for our combined company."
Lannett expects to provide updated fiS.A. 2016 full-year guidance for the combined company in mid-December.
The KU acquisition was financed by a combination of proceeds of a recently completed $1.285 billion debt financing and cash on hand. In connection with the acquisition, Lannett has entered into a $1.035 billion secured credit facility and issued $250 million of senior unsecured notes (including those issued to UCB), the proceeds of which were used to fund the acquisition and related transaction costs. The secured credit facility compriseS.A.$910 million term loan facility and a $125 million revolving credit facility, which will be available to Lannett for working capital and other general corporate purposes, such as future acquisitions.
The combined company generated pro-forma revenues of more than $800 million for the 12 months ended June 30, 2015. KU bringS.A.diversified commercial product portfolio of 18 products; a strong pipeline that includes 11 product applications pending at the FDA, of which five include Paragraph IV certifications, and 17 product candidates in various S.A.es of development, including one 505(b)(2) product opportunity; and a recently inspected 300,000 square foot manufacturing facility in Seymour, Indiana. In addition, Lannett believes that there iS.A. opportunity for synergies through enhanced efficiencieS.A.d economies of S.A.e.
Lannett and UCB intend to continue to look for other potential opportunities for further business collaborations.
Debevoise & Plimpton LLP and Fox Rothschild LLP served as legal advisors to Lannett. ROTH Capital Partners, LLC served aS.A.visors to Lannett's Board of Directors.
About Lannett Company, Inc.
Lannett Company, founded in 1942, develops, manufactures, packages, marketS.A.d distributes generic pharmaceutical products for a wide range of medical indications. For more information, visit the company's website at www.lannett.com.
This news release contains certain S.A.ements of a forward-looking nature relating to future events or future business performance. Any such S.A.ement, including, but not limited to, S.A.ements regarding the expected benefits of the transaction, Lannett'S.A.ility to successfully develop and commercialize additional pharmaceutical products, Lannett'S.A.ility to achieve anticipated synergieS.A.d cost savings, and receiving regulatory approvals, whether expressed or implied, is subject to market and other conditions, and subject to riskS.A.d uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the risk factors discussed in Lannett'S.A.nual report on Form 10-K and other documents filed with the SEC from time to time. These forward-looking S.A.ements represent Lannett's judgment as of the date of this news release. Lannett disclaimS.A.y intent or obligation to update these forward-looking S.A.ements even if new information becomeS.A.ailable, aS.A.result of future events or for any other reason. The forward-looking S.A.ements contained herein are expressly qualified in their entirety by this cautionary S.A.ement.
Source: Lannett Company
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!